PhD, Johns Hopkins Bloomberg School of Public Health, 2004
ScM, Johns Hopkins Bloomberg School of Public Health, 1999
MHS, Johns Hopkins Bloomberg School of Public Health, 1999
BS, University of California, San Diego, 1997
My primary research area is in infectious disease epidemiology specifically related to HIV and SARS-CoV-2. Within HIV, I have primarily been focusing on HIV care continuum, risk of cancer, and the intersection of substance use (e.g., alcohol) with HIV clinical outcomes. With SARS-CoV-2 pandemic beginning in the US in 2020, much of my research focus has shifted to COVID-19 related research. This includes two randomized clinical trial of convalescent plasma among persons with high risk exposure to SARS-CoV-2 and individuals with mild ambulatory infections. Additionally, I am involved in a modeling study examining strategies for allocating convalescent plasma in the current setting of vaccine rollout. Finally, my colleagues and I have recently launched a study to examine how symptoms of COVID-19 evolve from the initial acute phase of infection to the post-acute stage including trying to understand who is and is not at risk for developing post-acute COVID-19 syndrome (a.k.a. long COVID-19).
My research interests also include epidemiological and statistical methods for cohort (both clinical and interval) studies and application of these methods. I have specific interest in developing new methods as well as adapting approaches from other fields as novel solutions to specific epidemiologic questions.
I am involved with multiple ongoing studies including the Johns Hopkins HIV Clinical Cohort Study, the CFAR Network of Integrated Clinical Systems (CNICS), Alcohol Research Consortium in HIV (ARCH), Medicaid Cancer (MediCan) Study, and am the director for the Biostatistics and Epidemiology Methodology Core of the Johns Hopkins CFAR.
Honors and Awards
2016 Editor’s Choice for: Buchacz K, Lau B, Jing Y, et al. Incidence of AIDS-Defining Opportunistic Infections in a Multicohort Analysis of HIV-infected Persons in the United States and Canada, 2000-2015. Journal of Infectious Diseases 2016; 214:862-872. doi: 10.1093/infdis/jiw085
2015 Editor’s Choice for: Cole SR, Lau B, Eron JJ, et al. Estimation of the standardized Risk Difference and Ratio in a Competing Risks Framework: Application to Injection Drug Use and Progression to AIDS After Initiation of Antiretroviral Therapy. American Journal of Epidemiology 2015; 181:238-245.
2013 Inducted into Delta Omega Honorary Society in Public Health, Alpha Chapter, Johns Hopkins Bloomberg School of Public Health
2012 Editor’s Choice for: Silverberg MJ, Lau B, Justice AC, et al. Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis 2012;54:1026-1034